0001603978-26-000066 | 10-Q | XBRL Viewer | Aquabounty Technologies INC

Basis of Presentation

3 Months Ended

Mar. 31, 2026

3. Basis of Presentation

The unaudited interim condensed consolidated financial statements include the accounts of AquaBounty Technologies, Inc. and its wholly owned direct subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.

year. The unaudited interim condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.

Discontinued Operations

As noted above, the Company sold its Indiana Farm in July 2024 and its Canadian Farms in March 2025. At December 31, 2025, the Company determined that its actions and decisions during 2025 regarding its Ohio Farm Project constituted a triggering event for revaluing these assets. These farms have been designated as discontinued operations in these interim condensed consolidated financial statements for all periods presented (see Note 5).

Net (Loss) Income Per Share

Basic and diluted net income or loss per share available to common stockholders has been calculated by dividing net income or loss by the weighted average number of shares of common stock outstanding during the period. Basic net income or loss per share is based solely on the number of shares of common stock outstanding during the period. The calculation of fully diluted net income per share includes the number of shares of common stock issuable upon the exercise of vested options with an exercise price less than the fair value of the common stock and unvested stock awards, less the hypothetical number of shares of common stock that could be repurchased with stock option proceeds and unrecognized stock compensation.

For the periods with a net loss, all potential shares of common stock are considered anti-dilutive and are excluded from the calculation of diluted net loss per share. For the periods with net income, all potential shares of common stock would be anti-dilutive and are excluded from the calculation of diluted net income per share, because the Company has no vested options with an exercise price less than the fair value of the common stock and unrecognized stock compensation on unvested stock awards would be able to purchase more shares of common stock than the number of unvested stock awards.

The following table contains the Company’s potentially dilutive securities:


	Three Months Ended March 31,
Weighted Average Outstanding	2026	2025
Stock options	37,962	60,686
Prefunded warrants	36,110	—
Unvested stock awards	—	11,167
Total	74,072	71,853

Accounting Pronouncements

In November 2024, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2024-03, Disaggregation of Income Statement Expenses, to enhance the transparency of certain expense disclosures. The update requires disclosure of specific expense categories in the notes to the financial statements at interim and annual reporting periods. The update requires disaggregated information about certain prescribed expense categories underlying any relevant income statement expense caption. The amendments in this update are effective for public entities for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The amendments may be adopted either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impacts of this update and plans to adopt these amendments for annual disclosures for the year ended December 31, 2027, and interim disclosures in the year ended December 31, 2028.

Management does not expect any other recently issued, but not yet effective, accounting standards to have a material effect on its results of operations or financial condition.

Going Concern Uncertainty	3 Months Ended
Mar. 31, 2026
Going Concern Uncertainty [Abstract]
Going Concern Uncertainty	2. Going Concern Uncertainty Since inception, the Company has incurred cumulative net losses of $389 million and expects that this will continue for the foreseeable future. As of March 31, 2026, the Company had $441 thousand in cash on its condensed consolidated balance sheet. The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital, including its ability to sell assets to generate liquidity to fund ongoing operations, and there can be no assurance that such capital will be available in sufficient amounts, on a timely basis, or on terms acceptable to the Company, or at all. Limited operating assets, dependency on capital raising activities and cumulative net losses raises substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of this uncertainty. During the year ended December 31, 2025, the Company’s management continued to sell assets to generate cash for working capital, while exploring strategic alternatives to raise funds with the goal of maximizing stockholder value. Potential alternatives that were evaluated included, but were not limited to, equity or debt financing, a merger, and the sale of all or part of the Company. On February 11, 2026, the Company completed an equity transaction with certain investors, pursuant to which the Company sold an aggregate of 1,269,509 shares of its common stock, par value $0.001 (“Common Stock”) and pre-funded warrants to purchase an aggregate of 67,706 shares of Common Stock for gross proceeds of $1.15 million.

Going Concern Uncertainty

3 Months Ended

Mar. 31, 2026

Going Concern Uncertainty [Abstract]

Going Concern Uncertainty

2. Going Concern Uncertainty

Since inception, the Company has incurred cumulative net losses of $389 million and expects that this will continue for the foreseeable future. As of March 31, 2026, the Company had $441 thousand in cash on its condensed consolidated balance sheet.

The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital, including its ability to sell assets to generate liquidity to fund ongoing operations, and there can be no assurance that such capital will be available in sufficient amounts, on a timely basis, or on terms acceptable to the Company, or at all. Limited operating assets, dependency on capital raising activities and cumulative net losses raises substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of this uncertainty.

During the year ended December 31, 2025, the Company’s management continued to sell assets to generate cash for working capital, while exploring strategic alternatives to raise funds with the goal of maximizing stockholder value. Potential alternatives that were evaluated included, but were not limited to, equity or debt financing, a merger, and the sale of all or part of the Company.

On February 11, 2026, the Company completed an equity transaction with certain investors, pursuant to which the Company sold an aggregate of 1,269,509 shares of its common stock, par value $0.001 (“Common Stock”) and pre-funded warrants to purchase an aggregate of 67,706 shares of Common Stock for gross proceeds of $1.15 million.

Stockholders' Equity

3 Months Ended

Mar. 31, 2026

Stockholders' Equity [Abstract]

Stockholders' Equity

8. Stockholders’ Equity

The Company’s stockholders have authorized 80 million shares of stock, of which 5 million are authorized as preferred stock and 75 million as common stock (see Note 12).

Recent Issuances of Common Stock and Warrants

On February 11, 2026, the Company completed an equity transaction with certain investors, pursuant to which the Company sold an aggregate of 1,269,509 shares of its Common Stock and pre-funded warrants to purchase an aggregate of 67,706 shares of Common Stock for gross proceeds of $1.15 million. The warrants can be converted to Common Stock at the option of the holder and there is no expiration date.

Share-based compensation

At March 31, 2026, the Company has reserved 37,594 and 0 shares of common stock issuable upon the exercise of outstanding stock options and unvested stock awards, respectively, under its 2016 Equity Incentive Plan. No shares of common stock are reserved for future equity awards under the 2016 Equity Incentive Plan.

Unvested Stock Awards

During the three months ended March 31, 2026 and 2025, the Company expensed $0 and $24 thousand, respectively, related to the stock awards.

Stock options

The Company’s option activity is summarized as follows:


	Number of ‎options	Weighted ‎average ‎exercise price
Outstanding at December 31, 2025	38,919	$	42.95
Forfeited	—		—
Expired	(1,325)		83.08
Outstanding at March 31, 2026	37,594	$	41.53
Exercisable at March 31, 2026	36,738	$	42.33

Unless otherwise indicated, options issued to employees, members of the Board of Directors, and non-employees generally vest over a period of one year to three years and are exercisable for a term of 10 years from the date of issuance. There were no stock options granted during the three months ended March 31, 2026.

There was no intrinsic value for options outstanding or exercisable at March 31, 2026 and December 31, 2025.

The following table summarizes information about options outstanding and exercisable at March 31, 2026:


Weighted ‎average exercise ‎price of outstanding ‎options	Number of ‎options ‎outstanding	Weighted ‎average remaining ‎estimated life ‎(in years)	Number of ‎options ‎exercisable
< $10.00	13,673	7.2	12,817
$20.00 - $50.00	21,440	3.6	21,440
$100.00 - $200.00	931	5.0	931
$200.00 - $300.00	1,550	1.0	1,550
	37,594		36,738

Total share-based compensation on stock-option grants amounted to $5 thousand and $16 thousand for the three months ended March 31, 2026 and 2025, respectively. At March 31, 2026, the balance of unearned share-based compensation to be expensed in future periods related to unvested share-based awards was $0.

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2026

Stockholders' Equity [Abstract]

Stock Option Activity


	Number of ‎options	Weighted ‎average ‎exercise price
Outstanding at December 31, 2025	38,919	$	42.95
Forfeited	—		—
Expired	(1,325)		83.08
Outstanding at March 31, 2026	37,594	$	41.53
Exercisable at March 31, 2026	36,738	$	42.33

Information About Options Outstanding and Exercisable


Weighted ‎average exercise ‎price of outstanding ‎options	Number of ‎options ‎outstanding	Weighted ‎average remaining ‎estimated life ‎(in years)	Number of ‎options ‎exercisable
< $10.00	13,673	7.2	12,817
$20.00 - $50.00	21,440	3.6	21,440
$100.00 - $200.00	931	5.0	931
$200.00 - $300.00	1,550	1.0	1,550
	37,594		36,738

Discontinued Operations And Assets Held for Sale (Disclosure of Reclassified Balance Sheets that Constitute Discontinued Operations) (Details) - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total current assets held for sale	$ 9,634,337	$ 9,552,454
Total current liabilities held for sale	7,422,727	7,476,254
Discontinued Operations, Held-for-Sale [Member] \| Indiana And Canadian [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Prepaid and other current assets	114,336	32,454
Property, plant and equipment	9,520,000	9,520,000
Total current assets held for sale	9,634,336	9,552,454
Accounts payable and accrued expenses	36,492	90,019
Current debt	7,386,235	7,386,235
Total current liabilities held for sale	$ 7,422,727	$ 7,476,254

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2026
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Debt (Terms and Conditions of Long-term Debt Outstanding) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
less: loan origination costs	$ (517,874)	$ (637,859)
Long-term debt, net	$ 3,786,126	3,486,141
Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate	18.00%
Maturity date	Apr 2027
Total debt	$ 4,304,000	$ 4,124,000

Segment Reporting (Narrative) (Details)	3 Months Ended
Segment Reporting (Narrative) (Details)	Mar. 31, 2026 segment
Segment Reporting [Abstract]
Number of Reportable Segments	1
Number of Operating Segments	1

Stockholders' Equity (Stock Option Activity) (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2026 $ / shares shares
Number of options
Outstanding, beginning balance \| shares	38,919
Expired \| shares	(1,325)
Outstanding, ending balance \| shares	37,594
Exercisable \| shares	36,738
Weighted average exercise price
Outstanding, beginning balance \| $ / shares	$ 42.95
Expired \| $ / shares	83.08
Outstanding, ending balance \| $ / shares	41.53
Exercisable \| $ / shares	$ 42.33

Stockholders' Equity (Narrative) (Details) - USD ($)		3 Months Ended
Stockholders' Equity (Narrative) (Details) - USD ($)	Feb. 11, 2026	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Stockholders' Equity
Authorized shares of common stock		75,000,000		75,000,000
Authorized shares of preferred stock		5,000,000
Authorized shares of common and preferred stock		80,000,000
Common stock shares sold	1,269,509
Pre-funded warrants issued to purchase of common stock	67,706
Proceeds from issuance of common stock	$ 1,150,000	$ 959,550
Unvested Stock Awards [Member]
Stockholders' Equity
Share-based compensation expense		0	$ 24,000
Stock Options [Member]
Stockholders' Equity
Share-based compensation expense		5,000	$ 16,000
Unearned share-based compensation expense in future periods		0
Intrinsic value of options outstanding		0		$ 0
Intrinsic value of exercisable options		$ 0		$ 0
Granted		0
Exercisable term		10 years
Minimum [Member] \| Stock Options [Member]
Stockholders' Equity
Award vesting period		1 year
Maximum [Member] \| Stock Options [Member]
Stockholders' Equity
Award vesting period		3 years
2016 Equity Incentive Plan [Member] \| Reserved for Future Equity Awards [Member]
Stockholders' Equity
Common stock reserved for future issuances (in shares)		0
2016 Equity Incentive Plan [Member] \| Unvested Stock Awards [Member]
Stockholders' Equity
Common stock reserved for future issuances (in shares)		37,594
2016 Equity Incentive Plan [Member] \| Stock Options [Member]
Stockholders' Equity
Common stock reserved for future issuances (in shares)		0

Income Taxes (Narrative) (Details)	3 Months Ended
Income Taxes (Narrative) (Details)	Mar. 31, 2026 USD ($)
Income Taxes [Abstract]
Federal income tax expense	$ 0
State income tax expense	0
Income tax expense (benefit)	0
Unrecognized income tax benefits	$ 0

Discontinued Operations And Assets Held for Sale (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended
	Mar. 31, 2025	Jul. 31, 2024
Ohio Farm [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset held for sale		$ 13,000
Indiana Farm [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Related transaction expenses		305
Canadian Farm [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 5,200
Outstanding debt	3,200
Related transaction expenses	$ 216
Equipment [Member] \| Indiana Farm [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets		$ 9,500

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2026	May 05, 2026
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Document Period End Date	Mar. 31, 2026
Document Transition Report	false
Entity File Number	001-36426
Entity Registrant Name	AquaBounty Technologies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3156167
Entity Address, Address Line One	233 Ayer Road
Entity Address, Address Line Two	Suite 4
Entity Address, City or Town	Harvard
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01451
City Area Code	978
Local Phone Number	648-6000
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AQB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,147,204
Entity Central Index Key	0001603978
Document Fiscal Period Focus	Q1
Amendment Flag	false

Nature of Business and Organization (Policy)	3 Months Ended
Nature of Business and Organization (Policy)	Mar. 31, 2026
Nature of Business and Organization [Abstract]
Nature of Business	AquaBounty Technologies, Inc. (the “Parent” and, together with its wholly owned subsidiaries, the “Company”) was incorporated in December 1991 in the State of Delaware for the purpose of conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. In 1996, the Parent obtained the exclusive licensing rights for a gene construct (transgene) used to create a breed of farm-raised Atlantic salmon that exhibit growth rates that are substantially faster than conventional Atlantic salmon.

Subsequent Events (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 07, 2026	Feb. 11, 2026
Subsequent Event [Line Items]
Common stock shares sold		1,269,509
Subsequent Event [Member] \| Private Placement [Member]
Subsequent Event [Line Items]
Convertible preferred stock, shares issued upon conversion	4,727,371
Preferred stock, shares issued to certain investor	27,386
Proceeds from issuance of preferred stock to certain investor	$ 500
Placement agent fee percentage of gross proceeds	7.00%
Subsequent Event [Member] \| Senior Notes [Member] \| Private Placement [Member]
Subsequent Event [Line Items]
Debt conversion, converted instrument, amount	$ 4,000
Debt conversion, accrued interest converted	$ 316
Series A Preferred Stock [Member] \| Subsequent Event [Member] \| Private Placement [Member]
Subsequent Event [Line Items]
Debt conversion, converted instrument, shares issued	236,367
Preferred stock, par or stated value per share	$ 0.01

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash	$ 440,678	$ 501,295
Prepaid expenses and other current assets	158,352	266,862
Current assets held for sale	9,634,337	9,552,454
Total current assets	10,233,367	10,320,611
Right of use assets, net	15,480	22,982
Total assets	10,248,847	10,343,593
Current liabilities:
Accounts payable and accrued liabilities	227,798	337,038
Accrued employee compensation	923,147	912,103
Other current liabilities	15,480	22,982
Current liabilities held for sale	7,422,727	7,476,254
Total current liabilities	8,589,152	8,748,377
Long-term debt, net	3,786,126	3,486,141
Total liabilities	12,375,278	12,234,518
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Common stock, $0.001 par value, 75,000,000 shares authorized; 5,147,204 and 3,877,695 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	5,147	3,878
Additional paid-in capital	387,331,517	386,368,222
Accumulated deficit	(389,463,095)	(388,263,025)
Total stockholders’ deficit	(2,126,431)	(1,890,925)
Total liabilities and stockholders’ deficit	$ 10,248,847	$ 10,343,593

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Costs and expenses
Sales and marketing		$ 6,613
General and administrative	$ 621,566	1,159,067
Total costs and expenses	621,566	1,165,680
Operating loss	(621,566)	(1,165,680)
Other (expense) income
Interest expense	(299,985)
Loan forgiveness		2,008,046
Other expense, net	(3,250)	(4,434)
Total other (expense) income	(303,235)	2,003,612
(Loss) income from continuing operations	(924,801)	837,932
Loss from discontinued operations	(275,269)	(436,797)
Net (loss) income	(1,200,070)	401,135
Other comprehensive income
Foreign currency translation gain		688,229
Comprehensive (loss) income	$ (1,200,070)	$ 1,089,364
Basic and diluted net (loss) income per share
Net (loss) income from continuing operation, per share, basic	$ (0.20)	$ 0.22
Net (loss) income from continuing operation, per share, diluted	(0.20)	0.22
Net (loss) income from discontinued operation, per share, basic	(0.06)	(0.11)
Net (loss) income from discontinued operation, per share, diluted	(0.06)	(0.11)
Total basic net (loss) income per share	(0.26)	0.11
Total diluted net (loss) income per share	$ (0.26)	$ 0.11
Weighted average number of common shares -
Weighted average number of shares outstanding, basic	4,564,479	3,866,733
Weighted average number of shares outstanding, diluted	4,564,479	3,866,733

Stockholders' Equity (Information About Options Outstanding and Exercisable) (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2026 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding	37,594
Number of options exercisable	36,738
Less than $10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average exercise price of outstanding options, upper limit \| $ / shares	$ 10.00
Number of options outstanding	13,673
Weighted average remaining estimated life (in years)	7 years 2 months 12 days
Number of options exercisable	12,817
$20.00 - $50.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average exercise price of outstanding options, lower limit \| $ / shares	$ 20.00
Weighted average exercise price of outstanding options, upper limit \| $ / shares	$ 50.00
Number of options outstanding	21,440
Weighted average remaining estimated life (in years)	3 years 7 months 6 days
Number of options exercisable	21,440
$100.00 - $200.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average exercise price of outstanding options, lower limit \| $ / shares	$ 100.00
Weighted average exercise price of outstanding options, upper limit \| $ / shares	$ 200.00
Number of options outstanding	931
Weighted average remaining estimated life (in years)	5 years
Number of options exercisable	931
$200.00 - $300.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average exercise price of outstanding options, lower limit \| $ / shares	$ 200.00
Weighted average exercise price of outstanding options, upper limit \| $ / shares	$ 300.00
Number of options outstanding	1,550
Weighted average remaining estimated life (in years)	1 year
Number of options exercisable	1,550

Debt (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
Debt (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Mar. 31, 2025	Oct. 28, 2025
Debt Instrument [Line Items]
Interest expense	$ 300	$ 0
Senior Notes [Member]
Debt Instrument [Line Items]
Amount borrowed			$ 4,000
Loan term	18 months
Interest rate	18.00%

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating activities
Net (loss) income	$ (1,200,070)	$ 401,135
Adjustment to reconcile net loss to net cash used in operating activities:
Share-based compensation	5,014	40,161
Loan forgiveness		(2,008,046)
Paid in kind interest	299,985
Changes in operating assets and liabilities:
Prepaid expenses and other assets	34,129	(518,245)
Accounts payable and accrued liabilities	(170,269)	(259,975)
Accrued employee compensation	11,044	(16,756)
Net cash used in operating activities	(1,020,167)	(2,361,726)
Investing activities
Proceeds from asset sales		3,721,116
Net cash provided by investing activities		3,721,116
Financing activities
Repayment of term debt		(232,194)
Proceeds from issuance of common stock and warrants, net	959,550
Net cash provided by (used in) financing activities	959,550	(232,194)
Effect of exchange rate changes on cash and cash equivalents		8,770
Net change in cash	(60,617)	1,135,966
Cash at beginning of period	501,295	230,362
Cash at end of period	440,678	1,366,328
Supplemental disclosure of cash flow information and non-cash transactions:
Interest paid in cash from discontinued operations	$ 145,701	16,903
Property and equipment included in accounts payable and accrued liabilities		$ 9,137,864

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2026	Dec. 31, 2025
Condensed Consolidated Balance Sheets [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares outstanding (in shares)	5,147,204	3,877,695
Common stock, shares issued (in shares)	5,147,204	3,877,695

Basis of Presentation (Schedule of Impact of Potentially Dilutive Securities Outstanding) (Details) - shares	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	74,072	71,853
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	37,962	60,686
Prefunded Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	36,110
Unvested Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		11,167

Condensed Consolidated Statements of Changes in Stockholders’ (Deficit) Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive loss [Member]	Accumulated Deficit [Member]	Total
Beginning balance (in shares) at Dec. 31, 2024	3,865,778
Beginning balance at Dec. 31, 2024	$ 3,866	$ 386,297,611	$ (688,229)	$ (369,772,538)	$ 15,840,710
Net income (loss)				401,135	401,135
Other comprehensive income			$ 688,229		688,229
Share-based compensation (in shares)	3,583
Share-based compensation	$ 3	40,158			40,161
Ending balance (in shares) at Mar. 31, 2025	3,869,361
Ending balance at Mar. 31, 2025	$ 3,869	386,337,769		(369,371,403)	16,970,235
Beginning balance (in shares) at Dec. 31, 2025	3,877,695
Beginning balance at Dec. 31, 2025	$ 3,878	386,368,222		(388,263,025)	(1,890,925)
Net income (loss)				(1,200,070)	(1,200,070)
Issuance of common stock and warrants, net (in shares)	1,269,509
Issuance of common stock and warrants, net	$ 1,269	958,281			959,550
Share-based compensation		5,014			5,014
Ending balance (in shares) at Mar. 31, 2026	5,147,204
Ending balance at Mar. 31, 2026	$ 5,147	$ 387,331,517		$ (389,463,095)	$ (2,126,431)

Prepaid and Other Current Assets (Schedule of Prepaid and Other Current Assets) (Details) - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Prepaid and Other Current Assets [Abstract]
Prepaid insurance	$ 23,958	$ 172,032
Prepaid other	134,394	94,830
Total prepaid expenses and other current assets	$ 158,352	$ 266,862